On Demand Webinars

AI simulates how cancer cells respond to therapy, guiding optimal treatment strategies.

Slight modifications to glycoproteins reveal critical insights into disease onset, state, and progression, making them a wellspring for biomarker discovery. 

Advanced machine learning methods generate de novo therapeutic proteins, unlocking new possibilities for more effective treatments.

Epithelial cells partner with tissue-resident memory cells to protect the lung during Streptococcus pneumoniae infection.

Antibodies that simultaneously target two distinct antigens overcome cancer therapy resistance by addressing antigenic diversity and diminished T cell action. 

Chimeric antigen receptor engineering is now possible for immune cells other than T cells, including macrophages and invariant natural killer T cells.

Advances in synthetic biology and automation accelerate high throughput antibody screening.

Scientists employ optogenetic tools to understand how the brain recovers from damage and generates sensory experiences.

Advanced histotechnology techniques enable accurate assessment of treatment outcomes, fueling pharmaceutical development. 

An innovative oligonucleotide synthesis approach streamlines gene assembly, providing researchers with autonomy and efficiency.

Optimizing the chemical architecture of siRNA improves its therapeutic potential for neurodegenerative disorders.

Direct cardiac reprogramming relies on the principles of transdifferentiation to convert specialized cells into new cell types that help repair the heart.